news PLpro inhibitors support immune response to COVID-19 in cell cultures 30 July 2020 | By Victoria Rees (Drug Target Review) Researchers have found that using GRL-0617, an PLpro inhibitor, in cell cultures blocked SARS-CoV-2 production and supported the cell immune response.
news Team suggest bradykinin system could be targeted by COVID-19 drugs 29 July 2020 | By Victoria Rees (Drug Target Review) Researchers say computational analyses suggest the bradykinin system may explain some of the symptoms of COVID-19, providing a drug target.
news LY6E identified as potential immunoprotein against SARS-CoV-2 29 July 2020 | By Victoria Rees (Drug Target Review) A study has demonstrated that the LY6E protein inhibits SARS-CoV-2 infection in human cell cultures, so a drug mimicking it could be a therapy for COVID-19.
news Seaweed extract outperforms remdesivir as COVID-19 therapy in vitro 27 July 2020 | By Victoria Rees (Drug Target Review) According to new research, sulfated polysaccharides extracted from seaweed were more effective at inhibiting SARS-CoV-2 infection in mammalian cells than remdesivir.
news Could the Nsp1 protein be a novel drug target for COVID-19? 20 July 2020 | By Hannah Balfour (Drug Target Review) A study of the SARS-CoV-2 nonstructural protein 1 (Nsp1) showed it can supress translation and inhibit anti-viral defence mechanisms, making it a potential target for drugs.
news Interferon deficiency and heightened inflammation are hallmarks of severe COVID-19, say researchers 15 July 2020 | By Hannah Balfour (Drug Target Review) The newly identified hallmarks of critical COVID-19 indicate a combination of interferon supplementation and anti-inflammatory therapies could be effective in treating patients with severe COVID-19 symptoms.
news Neurological complications of COVID-19 8 July 2020 | By Hannah Balfour (Drug Target Review) Researchers report COVID-19 can cause a range of severe neurological symptoms, which may be the main presentation of COVID-19 in some patients.
news Genomics England launches next-generation research platform 7 July 2020 | By Hannah Balfour (Drug Target Review) The genomic research platform will initially be used to help fast-track COVID-19 drug research and development, before being leveraged against other diseases, such as cancer.
news Novel targeting peptide shows promise against COVID-19 cytokine storm 3 July 2020 | By Hannah Balfour (Drug Target Review) Experimental peptide combination TAT CARMIL1 reduced collagen degradation as a result of cytokine storm in ex vivo study.
article The coronavirus: seasonality and host-specific action of a “sexy” killer 2 July 2020 | By Dr Ulrich Kutschera (University of Kassel) Dr Ulrich Kutschera outlines why more studies are necessary before the spread and deadliness of the novel coronavirus is fully understood.
news Study reveals how SARS-CoV-2 rewires human proteins for replication 1 July 2020 | By Victoria Rees (Drug Target Review) A team of researchers has analysed how SARS-CoV-2 hijacks the proteins in its host cells to aid replication and infect nearby cells.
news Therapies targeting AhRs and IDO1 could combat COVID-19, paper says 30 June 2020 | By Victoria Rees (Drug Target Review) Researchers have hypothesised that treatments targeting the downregulation of AhRs and IDO1 genes could reduce severity of COVID-19 infection.
news Six molecular targets for COVID-19 identified by researchers 30 June 2020 | By Victoria Rees (Drug Target Review) A study of blood samples from COVID-19 patients has allowed a team to reveal six molecular targets that could be used to develop treatments for the virus.
news X-rays reveal structure of SARS-CoV-2 protease at room temperature 29 June 2020 | By Victoria Rees (Drug Target Review) Researchers grew large crystals and used an X-ray machine with a less intense beam to elucidate the structure of the SARS-CoV-2 main protease at room temperature.
news Study identifies 68 genes associated with risk of severe COVID-19 26 June 2020 | By Victoria Rees (Drug Target Review) A study has revealed 68 protein-coding genes associated with risk of severe COVID-19, nine of which are targeted by drugs currently in clinical trials.
